Advanced Cell Technology’s Study Published in Leading Hematology

The study,which was previously only available in the online edition of the Journal, includes commentary from Dr. Eric Bouhassira of the Albert Einstein College of Medicine, a leading researcher in the field of hematology.

"This is a major milestone for embryonic stem cell development," said William Caldwell, CEO and Chairman of ACTC. "These cells were originally derived from hESC's that were developed using ACT's single blastomere technique. The company was the first to derive hemangioblast from hESC's, a result which has yet to be replicated outside of the ACT laboratories. The study shows that ACT can produce these cells in quantity, which as Dr. Bouhassira states in his commentary, is a critical step towards being able to produce a donor-less source of blood for transfusion in the future."

The study also demonstrated that the process produces viable RBCs with the functional properties of their naturally occurring counterparts, demonstrating that the created cells can be enucleated in vitro.

Read More